Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
Corporate culture and the attitude of management might be at the root of the current scandal over serious health damage resulting from the tainting of Kobayashi Kako’s antifungal drug itraconazole with the sleep inducer rilmazafone, believes a health ministry official…
To read the full story
Related Article
- MHLW Urges Drug Makers to Provide Timely, Appropriate Information When Product Shortages Occur
December 22, 2020
- MHLW Urges Drug Makers to Boost Manufacturing Control after Itraconazole Issue
December 15, 2020
- Fukui Pref. Govt Launches On-Site Inspection at Kobayashi Kako over Itraconazole Contaminated with Sleep Inducer
December 11, 2020
- FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
ORGANIZATION
- Patient Group Pushes Emergency Steps to Address Concerta Supply Imbalances
May 18, 2026
- Labor Group Urges Priority Supply of Petrochemical Products for Drug Manufacturing
May 15, 2026
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…